Asia Biopharma News

Bioreactors play a crucial role in the production of biological drugs, also known as biologics. These complex molecules derived from living organisms require a controlled and optimized environment for their efficient production. Bioreactors provide the necessary conditions for cell culture, allowing for the growth and cultivation of genetically engineered cells or microorganisms that produce the..

Syngene, a contract development and manufacturing organization (CDMO), has confirmed that its Bengaluru biologics facility will be operational in the second half of 2024 to support its US and European customers. The facility, as previously reported, will have 20 kL of single-use drug substance capacity and will feature two high-speed vial filling lines capable of filling up to one million vials ..

WuXi Biologics, a contract development and manufacturing organization (CDMO), has begun the construction of a $1.4 billion commercial biologics plant in Singapore. This new facility will complement a small-scale manufacturing plant that was opened in Singapore last year. The site, located in Tuas Biomedical Park, will be equipped with WuXi Bio's proprietary technical platforms and state-of-the-a..

Daiichi Sankyo, based in Tokyo, has significantly expanded its presence in the biosimilars market in Japan through a sales and marketing agreement with Amgen. This partnership involves the development and commercialization of nine biosimilar products.  The agreement comes at a time when Amgen has recently received FDA approval for a biosimilar of AbbVie's Humira and aims to establish a stronger ..

The United States government has been introducing a series of policies that could significantly impact the biotechnology industry, drawing considerable attention to how these changes might affect the domestic sector. While these policies are generally viewed as favorable for the domestic industry, experts emphasize the need for meticulous preparation due to the potential intensification of globa..

South Korea's leading vaccine company, SK Bioscience, is set to acquire a German firm renowned for its contract manufacturing services, placing it among the global top 10 in the vaccine contract manufacturing industry.On the 27th, SK Bioscience announced that it had signed an agreement to acquire a controlling stake in IDT Biologika, a CDMO (Contract Development and Manufacturing Organization) c..

March 8, 2024 The space will function as a manufacturing base for the next-generation pneumococcal conjugate vaccine candidate GBP410 SK bioscience has initiated a significant expansion of its vaccine manufacturing facility, L HOUSE, in Andong, Gyeongsangbuk-do, South Korea, to enhance its product pipeline. The expansion involves adding two floors to the current vaccine manufacturing unit, resul..

2024.06 At a press conference during the Bio International Convention (BioUSA) in San Diego, John Rim, CEO of Samsung Biologics, underscored the efficiency of expanding production facilities in Korea over building or acquiring foreign factories. This strategic approach is driven by a surge in orders, necessitating an expansion of production capabilities. CEO John Rim announced that the fifth pla..